An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch

Raphael P. Luber, Rhona O'Neill, Sukhpreet Singh, Esha Sharma, Georgina Cunningham, Sailish Honap, Susanna Meade, Shuvra Ray, Simon H. Anderson, Joel Mawdsley, Jeremy D. Sanderson, Mark A. Samaan, Zehra Arkir, Peter M. Irving*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Fingerprint

Dive into the research topics of 'An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch'. Together they form a unique fingerprint.

Medicine and Dentistry

Immunology and Microbiology

Biochemistry, Genetics and Molecular Biology

Neuroscience